Back to search

Article

Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and Cyclophosphamide

2024-12-02

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction:</bold> Adriamycin and cyclophosphamide (AC) combination chemotherapy is one of the common regimens used for breast cancer and in metastatic breast cancer with oligo-metastasis. (1) AC combination chemotherapy regimen is associated with adverse drug reactions like myelosuppression, gastrointestinal toxicity, cardiotoxicity, peripheral neuropathy, and hand-foot syndrom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4016a4c5-8a63-5957-8a9a-1391f3361c19
DOI
10.21203/rs.3.rs-5513178/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and CyclophosphamideDOI 10.21203/rs.3.rs-5513178/v1
Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and CyclophosphamideSemantic proximity
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Semantic proximity
Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.Semantic proximity
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patientsSemantic proximity
Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity
Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity
Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.Semantic proximity
Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.Semantic proximity
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.Semantic proximity
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.Semantic proximity
Genetic Polymorphisms in Glutathione S-Transferase (GST) Gene and Their Correlation with Toxicity of Chemotherapy in Breast Cancer Patients.Semantic proximity
Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities.Semantic proximity
Select a neighboring publication to make it the new centre.